Mark Pollack Email

SVP, Global Medical Affairs . Sage Therapeutics

Current Roles

Employees:
768
Revenue:
$97.7M
About
Sage Therapeutics is a clinical-stage biopharmaceutical company committed to developing novel medicines to transform the lives of patients with life-altering central nervous system (CNS) disorders. Sage's lead product candidate, ZULRESSO(TM) (brexanolone) injection, has completed Phase 3 clinical development for postpartum depression and a New Drug Application is currently under review with the U.S. Food and Drug Administration. Sage is developing a portfolio of novel product candidates targeting critical CNS receptor systems, including SAGE-217, which is in Phase 3 development in major depressive disorder and postpartum depression.
Sage Therapeutics Address
215 First Street
Cambridge, MA
United States

Past Companies

Pollack Biopharmaceutical ConsultingPresident
Argus CognitiveMember Board of Directors
Sage TherapeuticsSenior Vice President, Global Medical Affairs

#1 Startup Dataset

Growth rates, revenue data, direct competitors and contact details.